Breaking News

BMS Selects LabCorp as Preferred Provider

April 2, 2013

To provide global central lab services and biomarker testing for trials

Bristol-Myers Squibb has selected LabCorp Clinical Trials as a preferred provider for full-service global central lab services and biomarker testing. The five-year agreement builds on a long-standing partnership between the two companies. LabCorp has supported various early and late-stage clinical development programs for BMS.
 
“We are excited to expand our relationship with Bristol-Myers Squibb to provide a more flexible and integrated approach to laboratory testing services in support of their innovative clinical development pipeline,” said Dr. Mark Brecher, LabCorp’s chief medical officer.
blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Heavy Metals in Drug Products

    Heavy Metals in Drug Products

    Nikki Schopp, Team Leader in charge of ICP-MS, ICP-OES and AA testing, SGS||January 29, 2015
    The potential presence of trace amounts of heavy metals in drug products is a real cause for concern with regulators.

  • Microbiological Testing & Contamination Control

    Microbiological Testing & Contamination Control

    Daniel L. Prince, Ph. D., Christopher J. Waskewich, M.S., Kristah J. Kohan, B.S. and Danina G. Rinaldi, B.S. , Gibraltar Laboratories, Inc.||March 7, 2014
    An opinion on the microbial limit test with reference to harmonization.